Ipca LaboratoriesNSE:IPCALAB +1.36%90 PEG Ratio is 6.32 as of Jul. 03, 2026, which is 39% below its 10-year median of 10.32. GuruFocus rates NSE:IPCALAB with a GF Score™ of 90/100 and a GF Value™ of ₹1,598.15 (Fairly Valued). The stock has 4 warning signs investors should review. Among 349 Drug Manufacturers companies, Ipca Laboratories ranks worse than 83.09% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Ipca Laboratories's PEG Ratio or its related term are showing as below:
NSE:IPCALAB'
s PEG Ratio Range Over the Past 10 Years
Min: 1.43 Med: 10.32 Max: 66.03
Current: 6.05
During the past 13 years, Ipca Laboratories's highest PEG Ratio was 66.03. The lowest was 1.43. And the median was 10.32.
NSE:IPCALAB's PEG Ratio is ranked worse than 83.09% of 349
companies
in the Drug Manufacturers industry
Industry Median: 1.71
vs NSE:IPCALAB: 6.05
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Ipca Laboratories (NSE:IPCALAB) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Ipca Laboratories PEG Ratio Related Terms
Ipca Laboratories PEG Ratio Historical Data
* Premium members only.
The historical data trend for Ipca Laboratories's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ipca Laboratories's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ipca Laboratories PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ipca Laboratories's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Ipca Laboratories's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Ipca Laboratories (NSE:IPCALAB) has a PEG Ratio of 6.32 as of Jul. 03, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Ipca Laboratories and its competitors. This is 39% below median its historical median of 10.32. Over the past decade, Ipca Laboratories' PEG Ratio has ranged from 1.43 to 66.03. According to the industry distribution chart, Ipca Laboratories ranks #290 out of 349 companies in the Drug Manufacturers industry, placing it in the top 83.1%.
Is Ipca Laboratories' PEG Ratio too high?
Ipca Laboratories' current PEG Ratio of 6.32 is 39% below median its 10-year median of 10.32. Over the past 10 years, this metric has ranged from a low of 1.43 to a high of 66.03. The Drug Manufacturers industry median PEG Ratio is 1.71. Ipca Laboratories' value of 6.32 is 269.6% above this industry median. Based on the distribution chart, Ipca Laboratories ranks #290 out of 349 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ipca Laboratories has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ipca Laboratories' PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ipca Laboratories ranks #290 out of 349 companies for PEG Ratio. This places Ipca Laboratories in the lower half of its industry. The industry median PEG Ratio is 1.71. Ipca Laboratories' value of 6.32 is 269.6% above this benchmark. Historically, Ipca Laboratories' own PEG Ratio has ranged from 1.43 to 66.03 over the past decade. While the company's 10-year median is 10.32 vs. the industry median of 1.71, Ipca Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.71, based on 349 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ipca Laboratories's current PEG Ratio of 6.32 is 269.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Ipca Laboratories and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ipca Laboratories's current PEG Ratio is 6.32, which is 39% below median its own 10-year median of 10.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ipca Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Ipca Laboratories (NSE:IPCALAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,598.15, compared to a current price of ₹1,719.40 — trading 7.6% above its estimated fair value. The current PEG Ratio is 6.32, which is 39% below median its 10-year median of 10.32 and 269.6% above the Drug Manufacturers industry median of 1.71. Ipca Laboratories' overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Ipca Laboratories (NSE:IPCALAB), the current PEG Ratio is 6.32 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ipca Laboratories (NSE:IPCALAB) Overvalued in 2026?
Based on GuruFocus' analysis, Ipca Laboratories stock appears to be overvalued.
The current stock price of ₹1,719.40 is trading 7.6% above its estimated GF Value™ of ₹1,598.15.
GuruFocus considers Ipca Laboratories to be Fairly Valued.
Key valuation signals for NSE:IPCALAB:
PEG Ratio: 6.32 (39% below median its 10-year median of 10.32)
GF Value™: ₹1,598.15 vs. price of ₹1,719.40 (7.6% above fair value)
Industry Position: 269.6% above the Drug Manufacturers median (#290 of 349)
No single metric tells the full story. See the NSE:IPCALAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ipca Laboratories Ltd is a pharmaceutical company. The company's principal activity is the Development, Manufacturing, and Marketing of Pharmaceuticals Products. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), Losartan. The company has only one reportable primary business segment, pharmaceuticals.
90GF Score
Get the complete analysis for NSE:IPCALAB
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:IPCALAB has been successfully added to your 
